| answer text |
<p>The National Health Service in England funds abiraterone for eligible NHS patients
in line with recommendations published by the National Institute for Health and Care
Excellence (NICE). It has been recommended by the NICE for the treatment of metastatic
hormone-relapsed prostate cancer before chemotherapy is indicated, and for castration-resistant
metastatic prostate cancer previously treated with a docetaxel-containing regimen.</p><p>NHS
England is in the process of considering a clinical policy proposal for the use of
abiraterone as an off-label treatment option for patients newly diagnosed with high
risk, non-metastatic, hormone-sensitive prostate cancer, or in whom prostate cancer
has relapsed after at least 12 months without treatment. The policy proposal was sent
out to stakeholder testing between the 30 November and 14 December 2023, and will
now be considered by NHS England’s Clinical Priorities Advisory Group, who make recommendations
on NHS England’s approach to commissioning services, treatments, and technologies,
and considers which of these should be prioritised for investment.</p>
|
|
